<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">JCI Insight</journal-id>
<journal-id journal-id-type="iso-abbrev">JCI Insight</journal-id>
<journal-id journal-id-type="publisher-id">JCI Insight</journal-id>
<journal-title-group>
<journal-title>JCI Insight</journal-title>
</journal-title-group>
<issn pub-type="epub">2379-3708</issn>
<publisher>
<publisher-name>American Society for Clinical Investigation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32427585</article-id>
<article-id pub-id-type="pmc">7406252</article-id>
<article-id pub-id-type="publisher-id">136007</article-id>
<article-id pub-id-type="doi">10.1172/jci.insight.136007</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>TrkB agonists prevent postischemic emergence of refractory neonatal seizures in mice</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kipnis</surname>
<given-names>Pavel A.</given-names>
</name>
<email>pavelkipnis@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4023-1324</contrib-id>
<name>
<surname>Sullivan</surname>
<given-names>Brennan J.</given-names>
</name>
<email>SullivanB@kennedykrieger.org</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-7705-2878</contrib-id>
<name>
<surname>Carter</surname>
<given-names>Brandon M.</given-names>
</name>
<email>bcarte24@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kadam</surname>
<given-names>Shilpa D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Neuroscience Laboratory, Hugo W. Moser Research Institute, Kennedy Krieger Institute, Baltimore, Maryland, USA.</aff>
<aff id="A2"><label>2</label>Department of Neurology and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</aff>
<author-notes>
<corresp>Address correspondence to: Shilpa D. Kadam, Hugo W. Moser Research Institute at Kennedy Krieger, Johns Hopkins University School of Medicine, 707 North Broadway, 400H, Baltimore, Maryland 21205, USA. Phone: 443.923.2688; Email: <email>kadam@kennedykrieger.org</email> or <email>skadam1@jh.edu</email>.</corresp>
<fn>
<p><bold>Authorship note:</bold> PAK and BJS contributed equally to this work.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest:</bold> SDK is listed as an author on US patent 10525024B2, “Methods for rescuing phenobarbital-resistance of seizures by ANA-12 or ANA-12 in combination with CLP290.”</p>
</fn>
</author-notes>
<pub-date date-type="pub" iso-8601-date="2020-06-18T09:00:00-0400" publication-format="electronic">
<day>18</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date date-type="collection" iso-8601-date="2020-06-18T09:00:00-0400" publication-format="electronic">
<day>18</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>18</day>
<month>6</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>5</volume>
<issue>12</issue>
<elocation-id>e136007</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>1</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 American Society for Clinical Investigation</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>American Society for Clinical Investigation</copyright-holder>
</permissions>
<self-uri xlink:href="https://insight.jci.org/articles/view/136007">This article is available online at https://insight.jci.org/articles/view/136007</self-uri>
<abstract>
<p>Refractory neonatal seizures do not respond to first-line antiseizure medications like phenobarbital (PB), a positive allosteric modulator for GABA<sub>A</sub> receptors. GABA<sub>A</sub> receptor–mediated inhibition is dependent upon electroneutral cation-chloride transporter KCC2, which mediates neuronal chloride extrusion and its age-dependent increase and postnatally shifts GABAergic signaling from depolarizing to hyperpolarizing. Brain-derived neurotropic factor–tyrosine receptor kinase B activation (BDNF–TrkB activation) after excitotoxic injury recruits downstream targets like PLCγ1, leading to KCC2 hypofunction. Here, the antiseizure efficacy of TrkB agonists LM22A-4, HIOC, and deoxygedunin (DG) on PB-refractory seizures and postischemic TrkB pathway activation was investigated in a mouse model (CD-1, P7) of refractory neonatal seizures. LM, a BDNF loop II mimetic, rescued PB-refractory seizures in a sexually dimorphic manner. Efficacy was associated with a substantial reduction in the postischemic phosphorylation of TrkB at Y816, a site known to mediate postischemic KCC2 hypofunction via PLCγ1 activation. LM rescued ischemia-induced phospho–KCC2-S940 dephosphorylation, preserving its membrane stability. Full TrkB agonists HIOC and DG similarly rescued PB refractoriness. Chemogenetic inactivation of TrkB substantially reduced postischemic neonatal seizure burdens at P7. Sex differences identified in developmental expression profiles of TrkB and KCC2 may underlie the sexually dimorphic efficacy of LM. These results support a potentially novel role for the TrkB receptor in the emergence of age-dependent refractory neonatal seizures.</p>
</abstract>
<abstract abstract-type="graphical">
<p>
<graphic orientation="portrait" position="float" xlink:href="jciinsight-5-136007-g087.jpg"></graphic>
</p>
</abstract>
<abstract abstract-type="toc">
<p>The partial TrkB agonist LM22A-4 and full TrkB agonists deoxygedunin and HIOC rescue neonatal phenobarbital-refractory ischemic seizures in P7 CD-1 mouse pups.</p>
</abstract>
<kwd-group kwd-group-type="specialties">
<kwd>Development</kwd>
<kwd>Neuroscience</kwd>
</kwd-group>
<kwd-group kwd-group-type="keywords">
<kwd>Seizures</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution>Eunice Kennedy Shriver National Institute of Child Health and Human Development</institution>
<institution-id>https://doi.org/10.13039/100009633</institution-id>
</institution-wrap>
</funding-source>
<award-id>R01HD090884</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
</article>
</pmc-articleset>